RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference.
Company management will present at 10:00AM CT on Thursday, November 21st, 2024.
A live webcast of the event will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alyssa Horowitz
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.15 |
| Daily Volume: | 0 |
| Market Cap: | US$2.280B |
April 14, 2025 April 14, 2025 April 01, 2025 February 26, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
